Igc pharma announces additional phase 2 interim results highlighting cognitive benefits of igc-ad1 for alzheimer's treatment

Potomac, md.--(business wire)-- #ad--igc pharma announces additional phase 2 interim results highlighting cognitive benefits of igc-ad1 for alzheimer's treatment.

IGC Ratings Summary

IGC Quant Ranking